East Asia Pharmaceutical (605177.SH) announced that its wholly-owned subsidiary, Zhejiang Dongbang Pharmaceutical Co., Ltd., has obtained the active pharmaceutical ingredient registration certificate from South Korea's Ministry of Food and Drug Safety (MFDS). Cefclo is a second-generation cephalosporin antibacterial drug that can treat a variety of respiratory infections, urinary tract infections, ear, nose, and throat infections, and skin and soft tissue infections caused by susceptible bacteria.

The company's cefclo (enzyme method) active pharmaceutical ingredient has obtained the registration certificate for active pharmaceutical ingredient in South Korea, which marks that the company's cefclo (enzyme method) active pharmaceutical ingredient has obtained the access qualification in South Korea, and will bring positive effects to the company's expansion of the pharmaceutical market in South Korea, thus promoting the sales of the company's cefclo (enzyme method) active pharmaceutical ingredient in other overseas markets. The company's cefclo active pharmaceutical ingredient is produced by a biocatalytic process that is more environmentally friendly and safe, which can effectively enhance the safety of the production process and reduce the company's environmental costs, and has a good improvement effect on the period management costs.